Contact Supplier

Contact Supplier

To get in touch with UGA Biopharma GmbH, simply fill out the form below.

    Subscribe to Supplier

    Subscribe to Supplier

    .

    UGA Biopharma to show high speed cell line development platform at BIO-Europe Spring® 2021

    news-releasesUGA Biopharma GmbH
    March 9th 2021

    Hennigsdorf, Germany: UGA Biopharma GmbH, the leading-edge contract research and development organization (CRDO) for biologics and biosimilars, will return to the annual BIO-Europe Spring® biotech industry partnering conference, hosted in virtual format for 2021.

    UGA Biopharma, which has a long relationship with the BIO-Europe conference, will use this year’s digital edition to connect with potential customers for its high speed cell line development platform and ready-to-use biosimilar cell lines.

    First CHOice

    The UGA Biopharma team, led by Business Development & Marketing Manager, Dr. Marcel Nowak, will be emphasizing the efficacy of its proprietary high performance First CHOice® Media and Feeds in promoting high titer yields, high product quality and cell viability.

    The First CHOice® Medium is a cell culture medium optimized for CHO mammalian cell lines. In combination with CHOice® Feeds it has been optimized to boost the cell growth and productivity in batch, fed-batch and perfusion processes.

    The completely chemically defined, animal component and protein free First CHOice® Medium has been developed in close cooperation with customers using CHO-S, CHO-DG44 and CHO-K1 cell lines in order to minimize stress-related metabolites such as lactate and ammonia.

    Fast track cell line development

    The team will be able to demonstrate product capabilities using the event’s partneringONE® virtual meeting platform.

    UGA will also present its tailor made high speed cell line development platform that combines proven optimized high-yield expression vectors and proprietary CHO-DG44 cells with a highly integrated scheme of work packages, use of high-performance media and bioprocess development to achieve very compressed timelines for biologics and biosimilars.

    About UGA Biopharma

    UGA Biopharma GmbH is an experienced contract research and development organization of biologics and biosimilars with the capabilities to handle all necessary steps from cell line development and bioprocess development to the development of purification strategies and appropriate analytics.

    The company supplies its customers in Germany and abroad from its headquarter in Hennigsdorf, near Berlin. Several clients have used UGA products in clinical trials or in products that have received market authorization.

    UGA Biopharma GmbH CRDO activities are centered on cell line development for biologics and biosimilars, specializing in the development of stable expressing CHO cell lines and cell media for the production of biologics and biosimilars for biopharmaceutical companies. Typical clients are biopharma manufacturers, research institutions (like universities and research institutes) as well as start-ups and other CROs that need to outsource CLD, upstream, and/or downstream processing.

    UGA’s mission is to fulfil customer requests, recognizing industry needs for high titer, high quality and fast delivery timelines, along with robust CHO cell lines. To this end, UGA can deliver cell lines, reaching titers from 4 to 7 g/L, within four months of receiving the originator sequence.

    UGA has also developed its proprietary First CHOice® cell culture media and feeds platform to boost the productivity of cell lines. Furthermore, UGA Biopharma GmbH offers ready-to-use biosimilar cell lines, which allow clients interested in biosimilar development fast track access to a highly biosimilar cell line.

    Further information at: www.ugabiopharma.com.

    About BIO-Europe Spring® 2021

    BIO-Europe Spring® is a premier partnering conference that annually attracts an international “who’s who” from biotech, pharma and finance for high caliber networking.

    For 2021, the conference will be hosted online in virtual and digital format. It will remain a four-day event, opening March 22. It will feature more than 920 participating companies.

    Featuring a sophisticated partnering system, partneringONE®, the digital event will enable networking and meetings between financiers, innovators and companies across the life science value chain, from large biotech to start-ups.

    The event is organized by Informa Connect and EBD Group with more information at: https://informaconnect.com/bioeurope-spring/

    Resources

    Click on UGA Biopharma First CHOice media  for more information.

    UGA Biopharma to show high speed cell line development platform at BIO-Europe Spring® 2021

    Contact UGA Biopharma GmbH

    Simply fill out the form below to contact UGA Biopharma GmbH now.

    Send UGA Biopharma GmbH a Message